Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

Katrine R Schoennemann, Jon K Bjerregaard, Tine Hansen, Karin de Stricker, Morten F Gjerstorff, Helle A Jensen, Lene W Vestermark, Per Pfeiffer

    18 Citationer (Scopus)

    Abstrakt

    Until recently there has been no proven second-line therapy for patients with advanced gastro-esophageal cancer (GEC). Since 2004, Denmark has had a national health program where non-proven therapy can be offered to patients with advanced cancer, after approval by an expert panel appointed by the National Board of Health. This program has accelerated the introduction and implementation of new therapies in Denmark. Inspired by therapy in metastatic colorectal cancer, a combination of cetuximab and irinotecan (Cetiri) was chosen for second-line therapy in GEC patients. We report our experience with Cetiri as second-line therapy in patients with GEC.
    OriginalsprogEngelsk
    TidsskriftGastric Cancer
    Vol/bind14
    Udgave nummer3
    Sider (fra-til)219-25
    Antal sider7
    ISSN1436-3291
    DOI
    StatusUdgivet - 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum'. Sammen danner de et unikt fingeraftryk.

    Citationsformater